Allogeneic hematopoietic stem-cell transplantation (HSCT) in general, and haploidentical HSCT in particular, is a therapeutic approach for leukemias and especially acute myeloid leukemia (AML). Residual malignant disease is mitigated, in part, after transplantation by graft-versus-leukemia activity of donorderived T cells expressing ab T-cell receptors that recognize major and minor histocompatibility antigens on malignant cells. In situations of human leukocyte antigen (HLA)-mismatched HSCT, the extensive T-cell depletion of the allograft undertaken to prevent graft-versus-host disease results in delayed T-cell engraftment, increases the probability of infection by opportunistic pathogens and the possibility of relapse. However, the infused and engrafted allogeneic natural killer (NK) cells also contribute to controlling infections and the graft-versus-leukemia effect, 1 although using a different activation mechanism. Donor-derived NK cells engrafting after haploidentical HSCT and adoptive transfer of haploidentical NK cells have shown therapeutic effects. NK-cell alloreactivity resulting from appropriate killer cell Ig-like receptor (KIR)-ligand disparity in HLA haplotype-mismatched HSCT has resulted in improved engraftment, decreased incidence of leukemia relapse and increased survival rates in patients with AML 2 and possibly also in children with acute lymphoblastic leukemia. 3 Pre-transplant infusion of alloreactive NK cells has been shown to eliminate AML blasts and kill recipient T cells which may allow a reduction in the toxicity of the conditioning regimen. Furthermore, NK cellmediated eradication of recipient dendritic cells may offer protection against graft-versus-host disease and support an increased T-cell content in the allograft. 1 Infusion of haploidentical NK cells after lymphodepleting chemotherapy has also been used to treat subsets of patients with relapsed AML, 2 and this observation has formed the basis of clinical trials infusing haploidentical NK cells for patients with relapsed/recurrent neuroblastoma 4 and pediatric acute lymphoblastic leukemia.
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It is hypothesized that a KIR ligand-mismatched donor provides the best chance for achieving a clinical effect against an underlying malignancy. 2 Yet, not all patient-donor pairs apparently benefit with an allogeneic NK cell-mediated antitumor effect based on genotype predictions. The 'missing self'-recognition hypothesis 6 predicts that target cells are vulnerable to NK-cell lysis in the absence or alteration of major histocompatibility complex class I molecules, and that NK-cell attack can be blocked by inhibitory KIRs that recognize a subset of classical HLA class I molecules. As a result, HLA mismatches of an altered allelic repertoire, as in haploidentical HSCT, leads to KIR-ligand mismatch and alloreactive NK cell-mediated killing of tumor cells. Although a haploidentical donor is mismatched to the recipient on a genetic level, observed alloreactivity may not occur in part due to allelic KIR variants that may not allow for full receptor expression, 1 and the relative numbers of alloreactive NK cells lacking KIR for self-HLA class I molecules may vary dramatically. 7 Furthermore, as each KIR has the ability to recognize allotypic determinants that are shared by different HLA class I alleles, an HLA mismatch between NK cells and target cells does not inevitably lead to NK cell-mediated alloreactivity. 8 Although a prediction of therapeutic effectiveness may be approached with the combined use of genotyping and profiling of KIR and HLA on donor cells, this remains an approximation of the actual killing potential between donor NK cell and recipient targets as most available antibodies used to detect KIR expression do not distinguish between activating and inhibitory KIRs. 7 As we cannot predict the actual frequency of alloreactive NK cells from genotyping or phenotyping of donor-derived KIR haplotypes and recipient HLA, we developed an approach to select a donor that exhibits an NK-cell alloreactivity for HLA molecules expressed in the recipient. This was undertaken with a functional assay to directly measure NK-cell killing through KIR-ligand interactions based on a panel of targets with n 0401 alleles were amplified from cDNA using 5UTCE (5 0 GGGCGAATTCGCCCGAGATGCGGGTCATGGCGCCCC3 0 ) and 3UTCH (5 0 CCGCAAGCTTTCGGGGAGGGAACACAGGTCAGTGTG GGGAC 3 0 ) primers. The resulting PCR amplicon which encodes the full-length classical HLA class I antigen was cloned into the mammalian expression vector pcDNA3.1 (Invitrogen). A clone was isolated and the fidelity of the HLA class I gene was confirmed by DNA sequencing. DNA for each class I allele was transfected by electroporation into the HLA class I deficient human B-cell line, 721.221. 9 Antibiotic selection with G418 identified positive transfectants and class I expressing subclones were subsequently screened by flow cytometry using anti-HLA class I clone W6/32 as a primary antibody and PE-conjugated goat anti-mouse IgG as a secondary antibody. After flow cytometric identification of a population of transfected cells expressing class I HLA, the HLA-expressing 721.221 cells were subjected to single-cell sorting to obtain stable transfectants of a clonal nature. Three stable/clonal HLA class I transfectants (B Letters to the Editor enforced expression of individual HLA class I genes recognized by KIR (Figure 1 ), and tested using populations of NK cells that were predicted to kill based on KIR and HLA typing genotype.
A panel of putative NK-cell targets was developed using 721.221 parental B cells that do not express HLA class I molecules and 721.221 cells with enforced expression of the individual HLA alleles B n 5801, Cw n 0401 and Cw n 0702, which function as KIR ligands. 9 These ligands bind to three main NKcell inhibitory receptors, KIR3DL1, KIR2DL1 and KIR2DL2/3, respectively. NK-cell alloreactivity is determined by a balance of activating and inhibitory signaling, primarily through activating and inhibitory KIRs. Therefore, target cells expressing single HLA alleles were anticipated to identify donors with demonstrable NK cell-mediated alloreactivity, and the magnitude of killing would identify donors with the largest subset of alloreactive NK cells for a particular KIR-ligand mismatch ( Figure 1 ). The observed killing was compared against the predicated alloreactivity based on genotyping. NK-cell cytolysis of 721.221 cell transfectants was expected if: (1) HLA-KIR ligands were absent in the donor and in the target cells and/or (2) HLA-KIR ligands were present in the donor and absent in the target cells.
Normal blood samples were obtained from GCRC (Gulf Coast Regional Center) with peripheral blood mononuclear cells isolated using the Ficoll gradient. Peripheral blood mononuclear cells were HLA and KIR genotyped (Table 1) , and stored frozen until use. Although all donors had a complete KIR repertoire of the receptors tested for, they each had different combinations of HLA-KIR ligands present and thus different patterns of predicted NK-cell inhibition versus activation for cytolysis (Table 1) . NK cells were isolated from thawed peripheral blood mononuclear cells from five healthy donors using magnetic negative cell sorting with NK-cell isolation kit (Miltenyi Biotec, Auburn, CA, USA À CD56 þ and ranged from 37 to 88%. The bulk NK-cell populations were cocultured with the 721.221 cell panel in a standard 4-h chromium release assay at an effector to target ratio of 20:1, and the results were plotted as percentage inhibition relative to 721.221 parental lytic inhibition.
To evaluate NK cell-mediated killing from one donor to the next, we evaluated the ability of the HLA class I-transfected 721.221 cells to resist being lysed. Donors 2 and 4 demonstrated unpredicted NK-cell lytic inhibition of Cw n 0401-and Cw n 0702-modified 721.221 targets, respectively (Table 1 , boxes). We also examined the degree of inhibition between donor NK cells that were predicted to be alloreactive ( Figure 2 ). Donor 2 had predicted alloreactivity in the presence of allele Cw n 0401, yet moderate inhibition was observed. Donor 4 was predicted to be alloreactive in the presence of the Cw n 0702 allele, but rather displayed moderate inhibition. NK cells from donor 5 were predicted to be inhibited in the presence of all three alleles tested and although this was the case, the magnitude of inhibition was moderate for all three targets. As this donor expresses all three KIR ligands, the moderate inhibition may be interpreted as the donor having three populations of NK cells that are mutually exclusively inhibited by their corresponding ligand. Thus, as not all of the NK-cell This analysis also distinguished two groups of 2DS4 alleles, those carrying a deletion of 22 nucleotides (003, 004, 006, 007), and alleles carrying full-length allele. Genomic DNA was extracted from nucleated cells using the Qiagen DNA purification kit EZ1 DNA Tissue Card (Qiagen, Germantown, MD, USA). KIR typing was performed using PCR amplification combined with hybridization with oligonucleotide probes (PCR-SSOP).
For SSOP KIR genotyping, we used KIR SSO genotyping kits from One Lambda Inc. (Canoga Park, CA, USA). DNA was amplified with specific primers and products were incubated with beads labeled by specific oligonucleotide probes. Beads were collected by the Luminex 100 platform (Luminex Corporation, Austin, TX, USA) and analyzed using HLA Visual 2.2 (One Lambda Inc.) software. KIR typing was also performed by PCR amplification using sequence-specific primers (SSPs) using the Pel-Freeze Genotyping SSP KIR kit (Invitrogen/Pel-Freeze, Brown Deer, WI, USA) containing 21 locus-specific primer mixes. Donors were typed for alleles at HLA-A, B, C, DRB1, DRB3/4/5/ and DQB1 by PCR amplification and oligonucleotide hybridization by molecular methods using commercial kits (Invitrogen, Carlsbad, CA, USA, and One Lambda Inc.) that achieve intermediate resolution. The donors were also typed for these loci by high-resolution methods using PCR amplification and nucleotide sequencing (Abbott Laboratories, Abbott Park, IL, USA). Additional high-resolution tests for selected loci were performed in donors in whom an allele level mismatch could not be ruled out. Letters to the Editor populations are inhibited at once, there will be some activity from NK cells within each of these populations. In comparing the alloreactivity of donors 1 and 4, it is suggested that donor 1 has a greater subset of alloreactive NK cells in the presence of the Cw n 0702 allele. Similarly, in the comparison of donors 2 and 3, NK cells from donor 3 showed a greater magnitude of alloreactivity than did those from donor 2 in the presence of Cw n 0401. In aggregate, the genotype-based prediction of lytic potential for 721.221 cell transfectants failed to fully predict the actual lysis for two of five 'donor-recipient' pairs.
Overall, we noted marked discrepancies between the potential for alloreactivity based on KIR-ligand mismatches and the observed degree of cytolysis. Moreover, the ability to observe the actual lytic potential of bulk populations of NK cells enabled the magnitude of alloreactivity to be determined and compared between potential donors. Future applications of this NK cell-mediated killing assay will be to correlate survival data with magnitude of observed lysis of 721.221 cells and inhibition of observed lysis based on KIR-HLA binding. Indeed, this type of information may prove a valuable addition to the selection criteria for alloreactive NK-cell donors as the magnitude and proportion of alloreactive NK-cell repertoire are apparently not parameters that can be predicted solely from donor genotyping.
Detection of genes encoding for the receptors and ligands do not warrant the definition of a complete repertoire, as allelic variations in the receptors and other structural variations in the ligands, as well as other genes (for example, activating genes) may have an impact in defining the NK-cell repertoire. However, pairing functional and genetic studies may allow for the elucidation of the molecular basis of the NK-cell repertoire. We conclude that when a 'KIR-mediated anti-tumor effect' is desired, the donor and recipients should be selected on the basis of the combined information from observed and predicted lysis rather than using genetic studies alone.
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The authors declare no conflict of interest. The identification of those genes that are frequently mutated in malignancies is essential for a full understanding of the molecular pathogenesis of these disorders, and often for the provision of markers for the study of disease progression. Recently, mutation of the ASXL1 (additional sex combs 1) gene has been reported in 4 out of 35 patients (11%) with myelodysplastic syndromes (MDS) and in 17 out of 39 patients (43%) with chronic myelomonocytic leukemia (CMML), a disease classified as MDS/myeloproliferative disorder. 1 The mutations were all found in exon 12 of the gene and are predicted to lead to the truncation of the C-terminus of the protein, which contains a PHD finger. 1 The PHD finger is a structural motif found in nuclear proteins involved in chromatin modifications. The function of the human ASXL1 protein is poorly understood, but there is some evidence to suggest that it may represent a component of DNA-and/or histone-modifying complexes.
2 ASXL1 belongs to a family of three members that encode polycomb and mixed-lineage leukemia/trithorax chromatin modifier complexes.
2 Most recently, mutations of ASXL1 have been reported in 5 out of 64 (approximately 8%) patients with the myeloproliferative disorders essential thrombocythemia and primary myelofibrosis, and in 11 out of 63 (17%) patients with acute myeloid leukemia (AML). 3, 4 These data suggest that ASXL1 represents a new tumor suppressor gene, the inactivation of which may have an important role in the molecular pathogenesis of malignant myeloid disorders.
We have screened ASXL1 for mutations in a large group of patients with MDS, CMML and AML, in order to determine their frequency in these malignant myeloid disorders and to determine any association with specific MDS subtypes, karyotypic groups and disease progression. Moreover, we have determined the effect of these mutations on global gene expression patterns and gene pathways.
A total of 300 patients with MDS, AML or CMML and 111 healthy controls were included in this study. The study was approved by the ethics committees of the institutes involved (Oxford C00.196, Bournemouth 9991/03/E, Duisburg 2283/03, Stockholm 410/03, Pavia 26264/2002, PamplonaFapproval by the Investigational Review Boards at the University of Navarra) and informed consent was obtained. Genomic DNA was isolated from patient bone marrow or peripheral blood samples by phenol/chloroform extraction using standard methods and evaluated for quality and concentration using an ND-1000 spectrophotometer (Nanodrop, Wilmington, DE, USA).
All previously reported mutations of ASXL1 in hematological malignancies were found exclusively in exon 12 of the gene. 1, 3 Sequences spanning exon 12 of the ASXL1 gene were amplified by PCR from the DNA of 300 patient samples and 111 normal controls. Primers and amplification conditions were as previously published.
1 PCR products were purified and directly sequenced using the BigDye Terminator v1.1 cycle sequencing kit (Applied Biosystems, Foster City, CA, USA) and an ABI 3100 Genetic analyzer. Sequence data were analyzed using Mutation Surveyor V3.25 (Softgenetics, State College, PA, USA).
ASXL1 mutations were observed in 62 out of the 300 patients (21%; Table 1 ). ASXL1 mutations were found in 5 out of 79 MDS patients with refractory anemia (RA; 6%), in 17 out of 55 patients with either refractory anemia with excess blasts 1 (RAEB-1) or RAEB-2 (31%), and in 17 out of 67 patients with AML (25%; Table 1 ). Thus, the mutation frequency is relatively high in late MDS and AML, with a lower frequency across the spectrum of early MDS (Table 1) . Examining the mutation frequency by karyotype shows that the mutation is common in Table 1 ASXL1 mutations in our series of patients with malignant myeloid disorders Abbreviations: AML, acute myeloid leukemia; CMML, chronic myelomonocytic leukemia; MDS, myelodysplastic syndromes; RA, refractory anemia; RAEB-1, refractory anemia with excess blasts 1; RAEB-2, refractory anemia with excess blasts 2; RARS, refractory anemia with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS, refractory cytopenia with multilineage dysplasia and ringed sideroblasts. The frequency of ASXL1 mutations is shown in each disease subtype and in different karyotypic groups.
